VERA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-1.303

+81.01%

-1.240

+53.09%

-1.309

+9.05%

Estimates Revision

The market is revising Upward the revenue expectations for Vera Therapeutics, Inc. (VERA) for FY2026, with the revenue forecasts being adjusted by 4.04% over the past three months. During the same period, the stock price has changed by 61.88%.

Revenue Estimates for FY2026

Revise Upward

+4.04%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+4.92%

In Past 3 Month

Stock Price

Go Up

+61.88%

In Past 3 Month

10 Analyst Rating

Wall Street analysts forecast VERA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VERA is 68.22 USD with a low forecast of 45.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

10 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

45.00

Averages

68.22

High

100.00

Current: 0.000

Low

45.00

Averages

68.22

High

100.00

Wolfe Research

Andy Chen

Peer Perform -> Outperform

upgrade

$548

2026-01-06

New

Reason

Wolfe Research

Andy Chen

Price Target

$548

2026-01-06

New

upgrade

Peer Perform -> Outperform

Reason

As previously reported, Wolfe Research analyst Andy Chen upgraded Vertex Pharmaceuticals (VRTX) to Outperform from Peer Perform with a $548 price target. While the firm had previously argued that stock re-rating on the renal franchise would be delayed due to generalist involvement in chronic pain, three positive changes occurred. Namely, Otsuka priced much higher than its expectation, Vertex confirmed usage of priority review voucher and the recent momentum of Vera Therapeutics (VERA) suggests that buyside is baking in a negative-skewed result on povetacicept early 2026, says the analyst, who believes Vertex "may be due for a rebound."

Goldman Sachs

Buy

maintain

$55 -> $95

2025-12-19

Reason

Goldman Sachs

Price Target

$55 -> $95

2025-12-19

maintain

Buy

Reason

Goldman Sachs raised the firm's price target on Vera Therapeutics to $95 from $55 and keeps a Buy rating on the shares. Following FDA approval and unexpectedly high pricing of Otsuka's Voyxact, assumptions for Vera were revised to reflect a meaningfully larger TAM and higher pricing potential for the APRIL/BAFF inhibitor class in IgAN, the analyst tells investors in a research note.

BofA

Buy

maintain

$48 -> $66

2025-12-19

Reason

BofA

Price Target

$48 -> $66

2025-12-19

maintain

Buy

Reason

BofA raised the firm's price target on Vera Therapeutics to $66 from $48 and keeps a Buy rating on the shares. The firm's raised target reflects expected pricing for Vera's lead drug based on class competitor pricing, which results in peak IgAN revenue of $2.2B, up from a prior forecast of $1.7B, the analyst tells investors. The firm also incorporates Vera's recent equity raise, which it sees boosting the net cash position to $680M to support a strong mid-26 commercial launch, the analyst noted.

JPMorgan

Overweight -> NULL

downgrade

$99 -> $96

2025-12-19

Reason

JPMorgan

Price Target

$99 -> $96

2025-12-19

downgrade

Overweight -> NULL

Reason

JPMorgan lowered the firm's price target on Vera Therapeutics to $96 from $99 and keeps an Overweight rating on the shares. The firm updated models in the smid-cap biotechnology group.

TD Cowen

Buy

maintain

$60 -> $73

2025-12-05

Reason

TD Cowen

Price Target

$60 -> $73

2025-12-05

maintain

Buy

Reason

TD Cowen raised the firm's price target on Vera Therapeutics to $73 from $60 and keeps a Buy rating on the shares. The firm raised its target to basedon higher peak US sales of $1.64B in 2033.

JPMorgan

NULL -> Overweight

upgrade

$52 -> $99

2025-12-03

Reason

JPMorgan

Price Target

$52 -> $99

2025-12-03

upgrade

NULL -> Overweight

Reason

JPMorgan raised the firm's price target on Vera Therapeutics to $99 from $52 and keeps an Overweight rating on the shares. The firm is updating its model for Vera following multiple competitive updates for Voyxact (sibeprenlimab) in IgA Nephropathy, the analyst tells investors in a research note. With the evolving market dynamics, particularly total addressable market considerations, the firm sees the product as potentially strategically attractive, JPMorgan added.

Valuation Metrics

The current forward P/E ratio for Vera Therapeutics Inc (VERA.O) is -9.50, compared to its 5-year average forward P/E of -7.83. For a more detailed relative valuation and DCF analysis to assess Vera Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-7.83

Current PE

-9.50

Overvalued PE

-3.61

Undervalued PE

-12.05

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-5.07

Current EV/EBITDA

-8.99

Overvalued EV/EBITDA

-0.55

Undervalued EV/EBITDA

-9.59

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

27.01

Current PS

578.17

Overvalued PS

127.22

Undervalued PS

-73.20

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

VERA News & Events

Events Timeline

No data

News

9.0

01-09Newsfilter

PinnedVera Therapeutics Files BLA for Atacicept in IgAN, Target Action Date July 7, 2026

5.0

01-09Globenewswire

Vera Therapeutics Grants 344,750 Stock Options and RSUs to New Employees

9.0

01-08Fool

Vera Therapeutics Submits IgAN Drug Application, Receives FDA Priority Review

People Also Watch

Frequently Asked Questions

What is Vera Therapeutics Inc (VERA) stock price today?

The current price of VERA is 48.71 USD — it has increased 2.14 % in the last trading day.

What is Vera Therapeutics Inc (VERA)'s business?

Vera Therapeutics, Inc. is a late-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, it is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. It is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. It retains all global developmental and commercial rights to atacicept and MAU868.

What is the price predicton of VERA Stock?

What is Vera Therapeutics Inc (VERA)'s revenue for the last quarter?

Vera Therapeutics Inc revenue for the last quarter amounts to -83.93M USD, increased 68.53 % YoY.

What is Vera Therapeutics Inc (VERA)'s earnings per share (EPS) for the last quarter?

Vera Therapeutics Inc. EPS for the last quarter amounts to -62039000.00 USD, increased 67.12 % YoY.

What changes have occurred in the market's expectations for Vera Therapeutics Inc (VERA)'s fundamentals?

How many employees does Vera Therapeutics Inc (VERA). have?

Vera Therapeutics Inc (VERA) has 112 emplpoyees as of January 10 2026.

What is Vera Therapeutics Inc (VERA) market cap?

Today VERA has the market capitalization of 3.41B USD.